This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. Classification codes | C66 — malignant neoplasm of ureter (ureteral urothelial carcinoma; includes ureteropelvic junction) |
| B. Synonyms | Ureteral transitional cell carcinoma (Ureteral TCC), Ureteral urothelial carcinoma, upper tract urothelial carcinoma (UTUC), ureteral squamous cell carcinoma |
| C. Adult onset | Very high — occurs mainly at age 60–75. Three times more common in men than women. Metachronous ureteral cancer develops in 2–5% of patients with a history of bladder cancer. Rarer than renal pelvis cancer (C65), with a renal pelvis:ureter ratio of about 2:1. |
| Special Copayment Reduction: V193 | 5 years from the date of cancer patient registration | copayment 5% | |
Ureteral cancer is a rare malignancy classified, together with renal pelvis cancer, as upper tract urothelial carcinoma (UTUC). Anatomically, the renal pelvis and ureter are composed of the same transitional epithelium (urothelium), so their carcinogenic mechanisms, risk factors and treatment principles are nearly identical. The historical description of ureteral cancer developed in close connection with that of renal pelvis cancer.
Until the early 20th century, diagnosis of ureteral cancer relied on filling defects and ureteral strictures found on intravenous pyelography (IVP). Advances in ureteroscopy in the 1970s–80s enabled direct visualization and tissue sampling, and the introduction of flexible ureteroscopes and the holmium (Ho:YAG) laser in the 1990s greatly improved the accuracy of endoscopic diagnosis and treatment. Elucidation of the link between aristolochic acid (AA) and UTUC (the Balkans, Taiwan) applied equally to ureteral cancer research.
Radical nephroureterectomy (RNU) has been established as the standard treatment, and since the 2010s laparoscopic and robot-assisted surgery has been replacing open surgery. In 2021, erdafitinib (an FGFR inhibitor) was approved as a systemic therapy for FGFR-altered urothelial carcinoma, and EV+pembrolizumab (enfortumab vedotin + pembrolizumab) combination therapy is being established as the new first-line standard treatment for metastatic urothelial carcinoma.
The risk factors for ureteral cancer are mostly the same as for renal pelvis cancer (C65) and bladder cancer (C67). Smoking is the strongest risk factor, increasing the risk of ureteral cancer 2–5-fold. Exposure to industrial chemicals such as aromatic amines, polycyclic aromatic hydrocarbons (PAH) and benzene is associated with ureteral cancer risk. Aristolochic acid (AA) exposure likewise forms DNA adducts in the ureteral epithelium, promoting carcinogenesis, and patients with aristolochic acid nephropathy (AAN) have a high risk of ureteral cancer.
Lynch syndrome (MMR gene defects, especially MSH2 variants) is a genetic risk factor that markedly increases ureteral cancer risk. A history of bladder cancer is an important risk factor for metachronous ureteral cancer; after bladder cancer treatment, metachronous urothelial carcinoma develops in the upper tract (renal pelvis, ureter) in 2–5%. Chronic urinary tract infection, urinary stones and chronic ureteral irritation also act as risk factors. An association with long-term phenacetin use (analgesic nephropathy) has also been confirmed epidemiologically. These risk factors affect the entire urothelium (urothelial field effect), forming the background for multifocal, synchronous and metachronous urothelial carcinomas.
The genetic features of ureteral cancer are similar to those of renal pelvis cancer. FGFR3 variants are found at high frequency in ureteral urothelial carcinoma (more than 50%) and are associated with low-grade papillary tumors. FGFR3 activating variants sustain receptor phosphorylation even without FGF ligand, constitutively activating the RAS-MAPK and PI3K-AKT pathways. HRAS and KRAS variants are also observed. In high-grade invasive tumors, loss of TP53, RB1 and CDKN2A is the main molecular event.
In Lynch syndrome, loss of MMR gene function causes microsatellite instability (MSI-H), and an excellent response to immune checkpoint inhibitors (pembrolizumab) is expected in MSI-H ureteral cancer. ARID1A variants (SWI/SNF complex) are also observed in UTUC. In ureteral cancer associated with aristolochic acid exposure, TP53 A:T→T:A transversion variants are found as a characteristic mutational signature. TERT promoter variants are identified in ureteral cancer at a lower frequency than in bladder cancer. From a whole-genome perspective, UTUC shows molecular features of more FGFR3/HRAS variants and fewer RB1/TP53 variants than bladder cancer, consistent with the relatively common predominance of low-grade differentiation and papillary growth patterns.
Among upper tract urothelial carcinomas, ureteral cancer is rarer than renal pelvis cancer, accounting for about 1/3 of all UTUC (renal pelvis:ureter about 2:1). Ureteral cancer accounts for 1–2% of all urothelial carcinomas. Incidence is very low, at about 1 per 1 million population. Men have a 2–3 times higher incidence than women, and the main age of onset is 60–75 years. Incidence varies geographically and is higher in countries with high smoking rates and regions with heavy aristolochic acid exposure (Taiwan, the Balkan Peninsula, some East Asian countries).
Metachronous upper tract UTUC develops in 2–5% of bladder cancer patients, and conversely, metachronous intravesical urothelial carcinoma develops in 20–50% of UTUC patients. This pattern supports the 'urothelial field effect' concept, which regards the entire urinary tract as a site at risk of carcinogenesis. The exact incidence of ureteral cancer in Korea is hard to tally separately, but it is estimated to account for 1/3 of all UTUC. Ipsilateral bladder cancer or renal pelvis cancer often coexists, so multidisciplinary follow-up is important.
The pathophysiology of ureteral cancer follows the same urothelial carcinogenic pathway as renal pelvis cancer. Because the ureteral transitional epithelium is in direct contact with urine, it is exposed for long periods to carcinogens dissolved in urine (smoking metabolites, aromatic amines, aristolochic acid metabolites). These carcinogens form covalent adducts with the DNA of ureteral epithelial cells, inducing mutations, which become the starting point of a multistep carcinogenic process of gradually acquiring the capacity for cell proliferation, invasion and metastasis.
By molecular pathway, the core of low-grade papillary ureteral cancer is FGFR3 activating variants → constitutive activation of the RAS-MAPK and PI3K-AKT pathways, and tumors of this pathway grow slowly and have low invasive capacity. In contrast, in high-grade invasive ureteral cancer, defective DNA damage response from TP53 variants + defective G1/S checkpoint from RB1 loss combine to produce rapid proliferation and invasion. Because the ureteral wall is thinner than the bladder wall, invasion of T2 or deeper is reached more easily than in bladder cancer, which is the anatomic reason ureteral cancer is found at a higher stage at diagnosis than bladder cancer. Lymph node metastasis depends on the location in the ureter: the upper ureter spreads to perirenal lymph nodes, the middle to para-aortic nodes, and the lower to pelvic lymph nodes.
The most common symptom of ureteral cancer is hematuria (painless intermittent hematuria). Gross hematuria appears in 70–80%, and because it is painless it is easily ignored. Ureteral cancer must be ruled out in elderly patients with recurrent gross hematuria.
Flank pain or back pain is the second most common symptom. When a ureteral tumor partially or completely obstructs the ureteral lumen, upper urinary tract obstruction (ureteral obstruction) causes hydronephrosis and colicky pain. Tumors of the lower ureter are located near the bladder and may be accompanied by bladder irritation symptoms such as frequency, urgency and painful urination. With advanced disease, an abdominal or pelvic mass may be palpable along with systemic symptoms such as weight loss, generalized fatigue and loss of appetite. During follow-up after bladder cancer treatment, positive urine cytology or unexplained decline in renal function may be a clue to metachronous ureteral cancer.
On physical examination, early ureteral cancer usually has no specific findings. When kidney enlargement from hydronephrosis is severe, it may be palpable as an abdominal mass. On urinalysis, microscopic or gross hematuria is the key finding. When high-grade malignant cells are found on repeated urine cytology, urothelial carcinoma is strongly suggested, and if cystoscopy shows no bladder lesion, an upper tract origin is suspected.
On CT urography, intraureteral filling defects, ureteral stricture and hydronephrosis are characteristic imaging findings of ureteral cancer. On cystoscopy, efflux of bloody urine from the ureteral orifice may be observed, which is useful for lateralizing the ureteral lesion. On ureteroscopy, an intraureteral papillary tumor, ulcerative lesion or irregular mucosa strongly suggests ureteral cancer. When abdominal ultrasound shows hydronephrosis and unilateral renal dilatation, a ureteral tumor should be considered as a cause of ureteral obstruction.
There is no standard population screening program for ureteral cancer, because incidence is so low that screening the general population has a poor cost-effectiveness ratio. However, active surveillance is recommended for certain high-risk groups.
Lynch syndrome carriers (especially MSH2, MSH6 variants): UTUC is detected early through annual urine cytology and CT urography every 2–3 years. In patients with a history of bladder cancer, upper tract CT urography is performed periodically along with cystoscopic surveillance to detect metachronous ureteral cancer early. Patients with a history of aristolochic acid exposure need regular urine cytology and CT urography follow-up. For workers with occupational carcinogen exposure, including urinalysis in occupational health checkups is recommended. Asymptomatic hematuria (including microscopic hematuria) may be an early sign of urothelial carcinoma, so its cause should be actively investigated.
As for renal pelvis cancer, the key imaging test for diagnosing ureteral cancer is CT urography (CTU). The entire ureter is evaluated with 3-phase imaging including the precontrast, nephrographic and excretory phases. Intraureteral filling defects, ureteral wall thickening and proximal hydronephrosis are typical imaging findings of ureteral cancer. MRI is used to assess soft tissue invasion and as an alternative in patients with contraindications to contrast.
Direct endoscopic examination using ureteroscopy and ureteral biopsy are essential for confirmation. Because the ureteral lumen is narrow and biopsy tissue may be insufficient, modern flexible ureteroscopes and small biopsy instruments are used. Selective ureteral washing cytology and FISH (fluorescence in situ hybridization) are used as adjunctive diagnostics. When tissue is obtained, FGFR3 variant analysis and MMR protein immunohistochemistry are performed. Abdominal, pelvic and chest CT are performed for staging, with a bone scan added if bone metastasis is suspected. With severe hydronephrosis, measurement of glomerular filtration rate and a nuclear medicine renal scan are also considered to assess renal function.
As for renal pelvis cancer, the standard treatment of nonmetastatic ureteral cancer is radical nephroureterectomy (RNU). The ipsilateral kidney, the entire ureter and a bladder cuff including the ureteral orifice are resected en bloc. Open, laparoscopic and robot-assisted surgery are all possible, and minimally invasive surgery allows faster recovery with equivalent oncologic outcomes. Lymph node dissection contributes to staging and may improve prognosis in high-risk lesions.
When kidney preservation is needed (solitary kidney, reduced renal function, bilateral tumors), endoscopic resection or laser ablation via ureteroscopy is a kidney-sparing alternative. In this case, the risk of local recurrence within the ureter is high, so strict ureteroscopic surveillance is required. Preoperative neoadjuvant chemotherapy (MVAC, GC) and immediate postoperative intravesical mitomycin C instillation (to reduce bladder recurrence) are recommended. In metastatic ureteral cancer, the same systemic treatment principles as for bladder cancer apply: in cisplatin-eligible patients, GC (gemcitabine + cisplatin) or DDMVAC is first-line chemotherapy, with erdafitinib used for FGFR3 variant-positive disease, pembrolizumab for MSI-H, and enfortumab vedotin ± pembrolizumab in second line and beyond.
As with renal pelvis cancer, the prognosis of ureteral cancer is stage-dependent and generally poorer than that of bladder cancer.
| Stage | 5-year cancer-specific survival |
|---|---|
| Ta/T1 (mucosa/lamina propria) | 75–90% |
| T2 (invasion of muscle layer) | 50–70% |
| T3 (periureteral fat) | 30–50% |
| T4 / lymph node metastasis | 10–25% |
Prognostic factors include stage, histologic grade, lymph node metastasis, presence of residual ureter after surgery, and aristolochic acid exposure (tendency toward multifocality). Intravesical recurrence (development of bladder urothelial carcinoma) occurs in 20–50% after RNU, so postoperative cystoscopic surveillance is essential. MSI-H tumors respond well to immune checkpoint inhibitors and may have a relatively better prognosis.
The most important measures for preventing ureteral cancer are the same as for renal pelvis cancer (C65). Smoking cessation is key to reducing smoking-related ureteral cancer risk, and the risk of urothelial carcinoma decreases significantly 10 or more years after quitting. Banning herbal medicines containing aristolochic acid and patient education are particularly important in East Asia. Compliance with occupational health regulations that minimize exposure to occupational carcinogens such as aromatic amines is needed.
Genetic counseling for members of Lynch syndrome families and participation in early screening programs are the key strategies for early detection of ureteral cancer. In patients with a history of bladder cancer, metachronous ureteral cancer is detected early through regular CT urography follow-up of the upper tract. Adequate fluid intake (at least 1.5–2 L per day) dilutes the concentration of carcinogens in urine and helps lower the carcinogenic risk across the urothelium. A medical culture and patient education that do not neglect microscopic hematuria but evaluate it appropriately contribute to early diagnosis of ureteral cancer.